Prevalence and determinants of controlled hypertension in a German population cohort

BMC Public Health

Wolfgang Hoffmann²  Sebastian E Baumeister²  Thomas Fiss¹  Claudia Meinke-Franze²  Neeltje van den Berg² 

[1] German Center for Neurodegenerative Diseases, site Rostock/Greifswald, Ellernholzstrasse 1-2, 17487, Greifswald, Germany;University Medicine Greifswald, Institute for Community Medicine Ellernholzstrasse 1-2, 17487, Greifswald, Germany

关键词: Study of Health in Pomerania (SHIP);    Determinants of normotensive blood pressure;    Antihypertensive treatment;    Hypertension;   

Others  :  1162088
DOI  :  10.1186/1471-2458-13-594

 received in 2012-07-30, accepted in 2013-06-14,  发布年份 2013

【 摘 要 】

Background

Data of the German population-based cohort SHIP (Study of Health in Pomerania) were analysed to examine treatment rates, antihypertensive substances prescribed, and the proportion of hypertensive study participants reaching target values for blood pressure as well as determinants.

Methods

The study population was defined using baseline data of the cohort (collected between 1997 and 2001). Participants with blood pressure values ≥140/90 mmHg and/or antihypertensive medication with known hypertension and participants with risk-comorbidity (diabetes, stroke, angina pectoris, and/or myocardial infarction) and blood pressure values ≥130/80 mmHg were included. The analysis of treatment and target values was based on the 5-year follow-up of the cohort (collected between 2002 and 2006). Logistic regression was used to identify determinants for a normotensive blood pressure.

Results

3278 SHIP-participants with hypertensive blood pressure values were included (mean age: 55.5 years; SD 13.6, range 21–80 years). The raw hypertension prevalence was 50.9% (N = 1761). 58.7% (N = 1074) of all hypertensive patients reported some form of antihypertensive treatment. Thereof 65.1% (N = 728) received combination therapy. Of the patients without risk-comorbidity, 42.1% (N = 489) reached their target blood pressure values at the time of the 5-year follow-up of the cohort. Of the patients with any risk-comorbidity this proportion was only 21.7% (N = 131). Significant determinants for reaching the target values were being female and having antihypertensive combination therapy. Increasing age, having risk-comorbidities, and obesity were negatively associated with reaching the target values.

Conclusions

Both the proportion of participants receiving therapy and the number of participants reaching their target blood pressure values are very low. Combination therapy is associated with better blood pressure control as compared to mono therapy. However, even in the subgroup of hypertensive patients under combination therapy only 36% (both patients with and without comorbidity) reach target values.

【 授权许可】

   
2013 van den Berg et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Meisinger C, Heier M, Völzke H, Löwel H, Mitusch R, Hense HW, Lüdemann J: Regional disparities of hypertension prevalence and management within Germany. J Hypertens 2006, 24(2):293-299.
• [2]Löwel H, Meisinger C, Heier M, Hymer H, Alte D, Völzke H: Epidemiology of hypertension in Germany. Selected results of population-representative cross-sectional studies. Dtsch Med Wochenschr 2006, 131(46):2586-2591.
• [3]Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003, 289(18):2363-2369.
• [4]Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
• [5]Janhsen K, Strube H, Starker A: Gesundheitsberichterstattung des Bundes - Heft 43: Hypertonie. Berlin: Oktoberdruck AG; 2008.
• [6]Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology, et al.: 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25(6):1105-1187.
• [7]German Hypertension Society: Leitlinien zur Behandlung der arteriellen Hypertonie. http://www.awmf.org/leitlinien/detail/ll/046-001.html webcite (accessed 21 July 2011)
• [8]Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, European Society of Hypertension, et al.: Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens 2009, 27(11):2121-2158.
• [9]German Hypertension Society: Neue Entwicklungen in der Hochdrucktherapie: eine Bewertung durch die Deutsche Hochdruckliga e.V. DHL, Deutsche Gesellschaft für Hypertonie und Prävention. [ http://www.awmf.org/leitlinien/detail/ll/046-001.html webcite] (accessed 24th July 2012)
• [10]Rahn KH: Differential hypertensive therapy according to the guidelines. Internist 2009, 50:433-441.
• [11]John U, Greiner B, Hensel E, Lüdemann J, Piek M, Sauer S, Adam C, Born G, Alte D, Greiser E, Haertel U, Hense HW, Haerting J, Willich S, Kessler C: Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed 2001, 46(3):186-194.
• [12]Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, Havemann C, Ittermann T, Schipf S, Haring R, Baumeister SE, Wallaschofski H, Nauck M, Frick S, Arnold A, Jünger M, Mayerle J, Kraft M, Lerch MM, Dörr M, Reffelmann T, Empen K, Felix SB, Obst A, Koch B, Gläser S, et al.: Cohort profile: the study of health in Pomerania. Int J Epidemiol 2011, 40(2):294-307.
• [13]Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen: Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahr 2006. Köln: DIMDI; 2008.
• [14]7.Guidelines Sub-Committee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999, 17:151-183.
• [15]Fiss T, Ritter CA, Alte D, van den Berg N, Hoffmann W: Detection of drug related problems in an interdisciplinary health care model for rural areas in Germany. Pharm World Sci 2010, 32(5):566-574.
• [16]McAlister FA, Wilkins K, Joffres M, Leenen FH, Fodor G, Gee M, Tremblay MS, Walker R, Johansen H, Campbell N: Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 2011, 183(9):1007-1013.
• [17]Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM: Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005, 14(11):795-803.
• [18]Turner BJ, Hollenbeak C, Weiner MG, Ten Have T, Roberts C: Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. Pharmacoepidemiol Drug Saf 2009, 18(8):672-681.
• [19]Borzecki AM, Oliveria SA, Berlowitz DR: Barriers to hypertension control. Am Heart J 2005, 149(5):785-794.
• [20]Schaefer M: Discussing basic principles for a coding system of drug-related problems: the case of PI-Doc. Pharm World Sci 2002, 24(4):120-127.